ALAS1 and acute intermittent porphyria: The management of a patient with acute intermittent porphyria typically starts with termination of potential causative medications and intravenous administration of glucose (300–400 g/24 h), which inhibits transcription of the gene encoding transhepatic 5’-aminolevulinate synthase 1 (ALAS1) [5, 9].